Roche Holding Ltd · SIX:RO
Roche — FY2023 Earnings Presentation
77 slides from Roche's earnings presentation, Feb 1, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2023 results
Roche 2023 results Basel, 1 February 2024
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: Performance Outlook
Performance Outlook
Slide 6: 2023 guidance exceeded
2023 guidance exceeded Guidance Results Group sales growth1 Low single digit decline +1% +6% Core EPS growth1 Broadly in line with sales decline (+1% excl. resolution of tax disputes in 2023) Dividend outlook Further increase dividend in Swiss francs2 CHF 9.60 1 At Constant Exchange Rates (CER); 2 2
Slide 7: 2023: Strong base business growth across both divisions
2023: Strong base business growth across both divisions Group sales +1% at CER driven by strong base business of +8% • Strong Pharma (+9% at CER) and Diagnostics (+7% at CER) base business growth • COVID-19 sales decreased by CHF -4.3bn and AHR by CHF -1.1bn, in line with guidance • Core OP margin s
Slide 8: 2023: Strong base business growth
2023: Strong base business growth Guidance exceeded with Group sales up by +1% at CER 2023 2022 Change in % Excl. CHFbn CHFbn CHF CER C191 Pharmaceuticals Division 44.6 45.6 -2 6 9 Diagnostics Division 14.1 17.7 -20 -13 7 Roche Group 58.7 63.3 -7 1 8 CER=Constant Exchange Rates; totals may include d
Slide 9: 2023: Base business more than compensates for COVID-19 impact
2023: Base business more than compensates for COVID-19 impact COVID-19 and AHR1 impact as expected; currency headwinds intensified throughout 2023 CHFm +1% at CER +945 -1,083 -1,069 +4,857 -3,259 -4,956 63,281 58,716 2022 Dia Dia Pharma Ronapreve AHR Fx 2023 base COVID-19 (excl. Ronapreve, sales ero
Slide 10: Quarterly growth including COVID-19
Acceleration of our growth momentum in 2023 Q4 2023 growth impacted by base effect from Ronapreve sales in Japan in 2022 14%* 14% 13% 12% 12% 11% Quarterly growth including COVID-19 10% 9% 9% 8% 8% 8% 7% 7% 7% 7% 6% 6% 6% 6% 6% 5% 4% 4% 4% 3% 2% 1% 1% 0% 0% 0% 0% -2% -4% -3% -4% -6% -6% Growth excl.
Slide 11: 2023: Base businesses in both divisions growing high single digit
2023: Base businesses in both divisions growing high single digit More than offsetting COVID-19 sales (CHF 4.3bn) erosion Pharma Diagnostics Quarterly sales evolution 2022-2023 Quarterly sales evolution 2022-2023 % CER % CER +30% +30% +24% +20% +20% +11% +9% +9% +7% +7% +8% +8% +7% +8% +10% +7% +10%
Slide 12: Key growth drivers of the Roche portfolio in 2023
Key growth drivers of the Roche portfolio in 2023 Establishing new leadership positions while further diversifying our portfolio Core Lab Molecular Lab -13% FY 2023 sales Pathology Lab Point of care (+7%)* (YoY CER growth) +2% Phesgo reaches CHF 1.1bn Diagnostics: +7% base business growth 14.1 16.1
Slide 13: Strategy and organizational development 2023
Strategy and organizational development 2023 Important progress made to set up the organization for continued success Strategy Innovation Organization People & Culture Digital Health strategy R&D Excellence Corporate Executive Committee Corporate Executive Committee • Portfolio focus defined • Produ
Slide 14: Pipeline update: Strengthening Pharma pipeline
Pipeline update: Strengthening Pharma pipeline Trade-offs made in Q4 to increase the overall portfolio value and speed up development NME and LE NME changes in Q4 (QoQ change, Q4 vs Q3) Phase Indication RG6468 I Solid tumors +1 2 RG6457 I Solid tumors ±0 6 8 +1 anti-TL1A II UC RG6382 I SLE -6* 12 8
Slide 15: Pipeline acceleration through partnering and acquisitions
Pipeline acceleration through partnering and acquisitions Recent deals increasingly focused on de-risked assets with significant potential * PoC RNA Molecular technology siRNA Dual GLP- therapies in Anti-TL1A in glue Generative with multiple targeting 1/GIP RA in ADCs in Alzheimer’s inflammatory deg
Slide 16: ESG achievements 2023
ESG achievements 2023 Sustainability is part of everything we do Reducing Scope 1 & 2 GHG WHO prequalification for HPV Novel antibiotic class with Top 3 position in DJSI emissions molecular test potential anti-CRAB activity2,3 Top 3 rank pRED & Harvard scientists Will help prevent 74m new Roche and
Slide 17: Performance Outlook
Performance Outlook
Slide 18: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term Two potential NME approvals expected for 2024: crovalimab in PNH and inavolisib in HR+ breast cancer CHFm % of Pharma Sales** 24,000 51% 44% 20,000 35% 16,000 12,000 24% * 8,000 4,000 0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 FY 2020
Slide 19: Declining COVID-19 related headwinds in 2024
Declining COVID-19 related headwinds in 2024 Q1 2024 is the final quarter materially impacted by declining COVID-19 sales CHFbn CER 3.0 CHF 4.3bn erosion CHF ~1.1bn erosion expected COVID-19 Tests Ronapreve 2.6 2.5 2.0 1.7 1.5 1.2 1.0 0.9 0.6 0.5 0.4 0.1 0.1 0.0 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q
Slide 20: Key growth drivers beyond 2025
Key growth drivers beyond 2025 Many opportunities with significant market potential in both divisions Pharmaceuticals Diagnostics NME Indication Newsflow Timing Product Description Launch tiragolumab NSCLC Final Ph III data H2 2024 Total solution for clinical mass i601 mass spec 2024 spectrometry an
Slide 21: Positive 2024 outlook
Positive 2024 outlook Sales drivers1 Continued strong base business growth in both divisions Group sales growth1 Mid single digit sales growth COVID-19 sales expected to decline by roughly CHF 1.1bn LOE2 impact of roughly CHF 1.6bn expected 1 At Constant Exchange Rates (CER); 2LOE impact includes gl
Slide 22: 2024 guidance
2024 guidance Group sales growth1 Mid single digit sales growth Broadly in line with sales growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 22
Slide 23: Finance
Finance Alan Hippe Chief Financial Officer
Slide 24: IR events currently planned for 2024
IR events currently planned for 2024 Additional events driven by readouts Neurology Update Diagnostics Day Pharma Day Mar 11 May 22 Sep 30 15:00 - 16:30 CET 13:00 - 15:30 BST tbd Virtual event London & virtual London & virtual • Neurology franchise update • Deep-dive into the current • Update on Gro
Slide 25: Results, Cash & balance sheet, Reporting changes
Results Cash & balance sheet Reporting changes Currency guidance & outlook
Slide 26: 2023: Group performance
2023: Group performance Sales increase of +1% and Core EPS increase of +6% 2023 2022 Change in % CHFm CHFm CHF CER Sales 58,716 63,281 -7 1 Core operating profit 19,240 22,173 -13 -1 as % of sales 32.8 35.0 Core net income 15,804 17,530 -10 3 as % of sales 26.9 27.7 Core EPS (CHF) 18.57 20.30 -9 6 I
Slide 27: 2023: Group operating performance
2023: Group operating performance Core OP lower by -1% due to higher operating expenses and lower other revenue (Ultomiris base effect 2022) 2023 2023 vs. 2022 CHFm abs. CER CER growth Sales 58,716 +391 1% Other revenue 1,725 -664 -27% Cost of sales -15,251 +1,350 -8% R&D -13,237 -709 5% SG&A -13,51
Slide 28: 2023: Core operating profit and margin
2023: Core operating profit and margin 46.4% 44.8% -0.4%p¹ % of sales +1.1%p² 35.0% excl. Ultomiris 32.8% -0.5%p¹ +0.6%p² excl. Ultomiris 24.7% CHFm 18.9% -1%¹ +2%² +5%¹ +8%² 22,173 -3.2%p¹ 21,131 19,240 19,989 -24%¹ 4,381 2,668 2022 2023 Roche Group Pharma Division Diagnostics Division Note: Group
Slide 29: 2023: Core net financial result
2023: Core net financial result Decrease due to increased interest expenses, partially offset by interest income CHFm • Net financial result decreased by -197m / +16% at CER • Interest expenses1 increased by -258m / +43% at CER -1,214 -1,300 +35 +162 -208 +127 -202 Full Year Equity Net interest Fx G
Slide 30: 2023: Group Core tax rate
2023: Group Core tax rate Decrease in core tax rate mainly due to higher impact from the resolution of tax disputes in 2023 compared to 2022 and lower profits from high tax jurisdictions -1.7%p 17.9% 1.5%p 16.2% 4.3%p Tax rate before resolution of tax 16.4% -4.5%p disputes 11.9% Effective tax rate E
Slide 31: 2023: Core EPS development
2023: Core EPS development Effects of resolutions of tax disputes in 2023 and increase in operations partially offset by Ultomiris base effect +6.1% +5.0% 21.87 +1.1% +2.5%p +5.0%p +0.3%p 20.84 20.62 -1.7%p FY 2022 Operations1 Base effect 2022: All other FY 2023 Resolutions of tax FY 2023 Ultomiris
Slide 32: 2023: Non-core and IFRS income
2023: Non-core and IFRS income Non-core operating exp. lower vs. PY due to lower impairments of IA partly offset by higher spend in GRP 2022 2023 Var. Change in % CHFm CHFm at CER CHF CER Core operating profit 22,173 19,240 -178 -13 -1 Global restructuring plans -969 -2,038 -1,153 Amortisation of in
Slide 33: Results, Cash & balance sheet, Reporting changes
Results Cash & balance sheet Reporting changes Currency guidance & outlook
Slide 34: 2023: Group Operating Free Cash Flow
2023: Group Operating Free Cash Flow OFCF +4%; NWC movement and lower IA investments partly offset by higher inv. in PP&E and declining cash OP +1,223 CHFm +173 +1,332 -109 -506 -230 -2,480 17,588 18,248 15,768 OFCF up by +4%/ +660m at CER Full Year start OP,cash Op net of net of adjustment cash NTW
Slide 35: 2023: Operating free cash flow and margin
2023: Operating free cash flow and margin 38.8% 39.7% % of sales 27.9% +2.3%p¹ 26.9% +0.9%p¹ 19.1% 11.9% CHFm +12%¹ -4.8%p¹ +4%¹ 17,673 17,694 17,728 15,768 3,382 -35%¹ 1,677 2022 2023 Roche Group Pharma Division Diagnostics Division Note: Group Operating free cash flow includes -3.6bn from Corporat
Slide 36: 2023: Group net debt development
2023: Group net debt development Net debt higher by CHF 3.1bn vs. YE 2022 Free Cash Flow CHF +11.3 CHFbn [PY: +13.0] [PY: -18.2] [PY: +17.7] [PY: -4.6] [PY: -10.5] [PY: -15.6] -4.5 Taxes -3.6 -15.6 +15.8 Treasury -0.9 -18.7 -14.4 Dividends paid -7.9 M&A & All. trans. -6.2 Curr. Transl. & Oth. +0.8 T
Slide 37: Balance sheet 31 December 2023
Balance sheet 31 December 2023 Equity ratio at 37% (31 Dec 2022: 36%) and net debt to assets at 21% (31 Dec 2022: 18%) % change in CER % change in CER vs 31 Dec 2022 vs 31 Dec 2022 CHFbn Cash and 90.5 +12% 90.5 88.2 88.2 +12% marketable 10.5 9.8 +19% securities 11% 12% Current 24.8 27.2 -2% Other 23
Slide 38: Results, Cash & balance sheet, Reporting changes
Results Cash & balance sheet Reporting changes Currency guidance & outlook
Slide 39: Restatements to be applied in 2024
Restatements to be applied in 2024 Foundation Medicine shifted to the Diagnostics Division effective Jan 1, 2024 Income statement (Core) Half Year 2023 Full Year 2023 Pharmaceuticals Division - CHFm Published Delta Restated Published Delta Restated Sales 22,681 -170 22,511 44,612 -347 44,265 Other r
Slide 40: Results, Cash & balance sheet, Reporting changes
Results Cash & balance sheet Reporting changes Currency guidance & outlook
Slide 41: 2023: Group currency exposure
2023: Group currency exposure Overall solid natural hedge Currency exposure 50% Sales Costs 46% 40% 43% 30% 30% 20% 19% 18% 16% 15% 10% 1% 7% 5% 0% CHF USD EUR JPY Others 41
Slide 42: 2023: Currency impact and outlook
2023: Currency impact and outlook CHF / USD 0% -3% -5% -6% In 2023 impact1 is (%p): 0.95 0.95 0.94 0.92 Q1 HY Sep FY 0.90 0.90 YTD 0.93 0.91 Sales -4 -6 -7 -8 0.92 0.92 0.93 0.90 0.90 0.90 0.87 0.88 0.90 0.90 0.89 0.87 Core Monthly avg fx rates 2023 Average YTD 2023 Average YTD 2022 operating -8 -12
Slide 43: 2023: Core EPS
2023: Core EPS 2023 Core EPS adjusted to CHF 18.02 is basis for Core EPS outlook 2024 at CER +0.42 18.99 -0.97 CHF 18.57 18.02 Core EPS 2023 2023 foreign Core EPS 2023 basis Excluding impact from Adjusted Core EPS as reported exchange losses: for outlook Core EPS resolution of tax disputes 2023 basi
Slide 44: 2024 guidance
2024 guidance Group sales growth1 Mid single digit sales growth Broadly in line with sales growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 44
Slide 45: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 46: 2023: Pharmaceuticals sales
2023: Pharmaceuticals sales All regions ex-Japan delivering strong growth, intensifying currency headwinds throughout 2023 2023 2022 Change in % CER w/o CHFm CHFm CHF CER Ronapreve Pharmaceuticals Division 44,612 45,551 -2 6 9 United States 23,606 23,322 1 8 8 Europe 8,306 8,143 2 6 7 Japan 3,745 4,
Slide 47: 2023: Pharmaceuticals core operating profit
2023: Pharmaceuticals core operating profit Core operating profit broadly in line with sales growth 2023 2023 vs. 2022 CHFm abs. CER CER growth Sales 44,612 +2,705 6% Other revenue 1,667 -656 -27% Cost of sales -8,343 +114 -1% R&D -11,490 -725 6% SG&A -7,215 -409 6% OOI&E 758 +25 3% Core operating p
Slide 48: 2023: Young portfolio delivering strong growth
2023: Young portfolio delivering strong growth Vabysmo sales exceed CHF 2bn and Phesgo achieves blockbuster status Vabysmo 324% Ocrevus 13% Hemlibra 16% Polivy 108% Phesgo 64% Evrysdi 39% Tecentriq 9% Gazyva 19% Tamiflu 133% Actemra / RoActemra 5% Alecensa 8% Xolair 5% Enspryng 49% TNKase / Activase
Slide 49: Strong Phesgo launch continues, now at 39% conversion rate
Oncology solid tumors Strong Phesgo launch continues, now at 39% conversion rate* Tecentriq SC achieves EU approval Q4 update Others CHFm 771 / +3% Herceptin • Perjeta: growth driven by International; Q4 sales impacted by an CHFm 1,626 / -16% adjustment in the reserves related to US government progr
Slide 50: Inavolisib more than doubles PFS in 1L PIK3CA-mut HR+ breast cancer
Oncology solid tumors Inavolisib more than doubles PFS in 1L PIK3CA-mut HR+ breast cancer Additional Ph III trials ongoing, including head-to-head vs. alpelisib and in combination with Phesgo Ph III development program Ph III (INAVO120) inavolisib in 1L PIK3CA-mut HR+ mBC1 Inavolisib 1L PIKC3A-mut H
Slide 51: Kadcyla as SoC in early HER2+ BC with residual invasive disease
Oncology solid tumors Kadcyla as SoC in early HER2+ BC with residual invasive disease First targeted therapy to show significant OS benefit in this patient population Ph III (KATHERINE) Kadcyla in HER2+ early-stage breast cancer 7-year OS data1 Herceptin Kadcyla (n=743) (n=743) No. of events, n (%)
Slide 52: Hemlibra reaches 40% patient share in US/EU5
Hematology Hemlibra reaches 40% patient share in US/EU5 Polivy US patient share in 1L DLBCL (IPI 0-5) climbing to 21% Q4 update • Hemlibra: continued penetration across all approved pts segments Mabthera/Rituxan with ~24,000 patients treated globally CHFm 1,261 / -15% • Positive Ph III (HAVEN 7) res
Slide 53: Ocrevus market leader in US/EU5 with 24% global patient share
Neurology Ocrevus market leader in US/EU5 with 24% global patient share Elevidys Ph III (EMBARK) results to be shared with health authorities Q4 update Others • Ocrevus: >300k patients treated globally; higher retention rate Enspryng CHFm 389 / -12% CHFm 256 / +49% than other MS medicines • Evrysdi:
Slide 54: Elevidys providing clinically meaningful benefits in DMD
Neurology Elevidys providing clinically meaningful benefits in DMD Ph III (EMBARK) results favoring Elevidys treatment on all key secondary endpoints Development program Ph III (EMBARK) in DMD topline results Favors Elevidys LSMean difference (95% CI) p-value 101 Ambulatory, 4-7 yrs. 102 Ambulatory,
Slide 55: Trontinemab in AD clears Aβ more rapidly than conventional mAbs
Neurology Trontinemab in AD clears Aβ more rapidly than conventional mAbs First Aβ-targeting antibody Brainshuttle™ with Ph Ib/IIa in Alzheimer’s disease currently ongoing Trontinemab Trontinemab clearly differentiated from other anti-Aβ mAbs (Brainshuttle™ anti-Aβ mAb) PFS (investigator assessed) P
Slide 56: Xolair in food allergy filed in the US, approval expected in Q1 2024
Immunology Xolair in food allergy filed in the US, approval expected in Q1 2024 Gazyva Ph III (REGENCY) in lupus nephritis to readout in 2024 Q4 update Others CHFm 1,067 / -36% • Xolair: growth driven by strong CSU performance; market shares in Asthma declining • Actemra: strong US performance in RA
Slide 57: Xolair: first medicine to reduce allergic reactions to multiple foods
Immunology Xolair: first medicine to reduce allergic reactions to multiple foods FDA priority review ongoing and decision expected for Q1 2024 Ph III (OUtMATCH) in food allergy study design* Unmet need1,2,3 Primary Objective: To compare the ability to consume foods The first 60 Stage 1: 17m Pts with
Slide 58: Anti-TL1A with first-in-class and best-in-disease potential in IBD
Immunology Anti-TL1A with first-in-class and best-in-disease potential in IBD Initiation of Ph III studies in IBD ongoing; additional potential in several other auto-immune diseases anti-TL1A (RVT-3101) Ph IIb (TUSCANY-2) anti-TL1A in ulcerative colitis DR3 Receptor DR3 DR3 Clinical remission & endo
Slide 59: Vabysmo reaching US market share of 22% in nAMD and 15% in DME
Ophthalmology Vabysmo reaching US market share of 22% in nAMD and 15% in DME* US approval for Vabysmo’s third indication RVO achieved Q4 update Susvimo Luxturna CHFm 3 / +54% • Vabysmo: 42% of US new patient starts are naive CHFm 44 /+4% Lucentis • US approval for Vabysmo in RVO achieved, 2 months a
Slide 60: Dual GLP-1/GIP agonist (CT-388) with best-in-class potential in obesity
Cardiovascular & Metabolism Dual GLP-1/GIP agonist (CT-388) with best-in-class potential in obesity Early stage readouts for all incretins expected in 2024; new trials to be initiated GLP-1/GIP RA (CT-388) Development program Molecule Indication Admin. Development stage 2024 readouts* Adenylyl cycla
Slide 61: 2023: Key newsflow
2023: Key newsflow* Compound Indication Milestone Hemlibra Moderate hemophilia A EU approval Polivy + R-CHP 1L DLBCL US approval Vabysmo RVO US approval/EU filing Tecentriq Subcutaneous administration US approval/EU filing US 2024 / EU filing Regulatory Columvi (glofitamab) 3L+ DLBCL US/EU approval
Slide 62: 2024: Key newsflow
2024: Key newsflow* Compound Indication Milestone Alecensa Adjuvant ALK+ NSCLC US/EU approval inavolisib + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC US/EU filing Tecentriq Subcutaneous administration US/EU approval EU crovalimab PNH US/EU approval Elevidys DMD EMA interaction ongoing Ocrevus 6m
Slide 63: Building blocks for mid- to long-term growth
Building blocks for mid- to long-term growth Recent acquisitions adding significant upside potential Telavant Alnylam Carmot acquisition partnership acquisition Oncology solid tumors Hematology CT-388 / Neurology anti-TL1A ASO Factor B zilebesiran CT-996 / CT-868 Ophthalmology Immunology anti-latent
Slide 64: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 65: 2023: Diagnostics sales
2023: Diagnostics sales Strong base business growth, partially offsetting COVID-19 sales decrease 2023 2022 Change in % Excl. CHFm CHFm CHF CER C191 Diagnostics Division 14,104 17,730 -20 -13 7 Core Lab 7,750 7,775 0 9 Molecular Lab 2,220 3,450 -36 -30 Pathology Lab 1,388 1,318 5 14 Point of Care 1,
Slide 66: Diagnostics sales growth by quarter
Diagnostics sales growth by quarter Strong base business growth in Q4 2023 24% 10% 8% 7% 8% 7% 8% 3% 4% 4% 0% -4% -9% -5% -17% Diagnostics Division sales growth -28% Base business sales growth1 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 1.9bn 1.2bn 0.6bn 0.5bn 0.3bn 0.1bn 0.1bn 0.4bn COVID-19 s
Slide 67: 2023: Diagnostics highlights
2023: Diagnostics highlights Strong base business growth, partially offsetting COVID-19 sales decrease CHFbn YoY CER growth • Immunodiagnostics (+10%) Core Lab +9% • Clinical Chemistry (+10%) • Custom biotech (-7%) • Cervical Cancer (+23%) • Blood Screening (+13%) Molecular Lab -30% • Virology base
Slide 68: 2023: Diagnostics regional sales
2023: Diagnostics regional sales Strong base business growth across all regions; significantly lower COVID-19 sales North America -21% EMEA ~27% of divisional sales -13% ~34% of divisional sales Asia Pacific Latin America -11% +14% ~32% of divisional sales ~7% of divisional sales Growth rates at CER
Slide 69: 2023: Diagnostics core operating profit
2023: Diagnostics core operating profit Decline due to drop in COVID-19 sales 2023 2023 vs. 2022 CHFm abs. CER CER growth Sales 14,104 -2,314 -13% Other revenue 58 -8 -12% Cost of sales -6,908 +1,236 -15% R&D -1,747 +16 -1% SG&A -2,899 -12 0% OOI&E 60 +22 50% 50% Core operating profit 2,668 -1,061 -
Slide 70: FDA Breakthrough Device Designation status for Elecsys NfL
FDA Breakthrough Device Designation status for Elecsys NfL Aids in detection of disease activity and progression of Multiple Sclerosis Role of NfL along patient journey for MS (disease burden ~3 million people2,3) Treatment selection Disease monitoring Treatment selection & Treatment & disease Patie
Slide 71: Elecsys Anti-HEV IgM & Anti-HEV IgG
Elecsys®Anti-HEV IgM & Anti-HEV IgG Combination test will enable diagnosis of acute and chronic infections for better patient management Interpretation of testing for HEV1 Unmet medical need • 20 million new annual infections, resulting in more than 70,000 deaths1,2 • ⅓ of global population at risk
Slide 72: navify Algorithm Suite
navify Algorithm Suite Providing trusted decision support for clinicians Algorithms Algorithm library Algorithm ✔ 15 certified & CE-marked output Healthcare algorithms available Patients Providers ✔ 20 algorithms in pipeline ✔ Key focus on cardiology & Integrated into LIS1 oncology or EMR2 workflow
Slide 73: LightCycler PRO
LightCycler PRO® First system labeled for research and IVD with broad portfolio of molecular diagnostics tests Differentiation Key applications • Rapid response to outbreaks and new pathogens Higher multiplexing capabilities (7 channels) to increase complexity of tests per run and throughput • Immun
Slide 74: Diagnostics key launches 2023
Diagnostics key launches 2023 Area Product Description Markets Status Modular transportation system, integrated into the existing cobas connection modules, allowing for overhead CCM Vertical Global sample transportation over different work areas or different floors enabling effective use of lab spac
Slide 75: Diagnostics key launches 2024
Diagnostics key launches 2024 Area Product Description Markets Status i601 mass spectrometry Launch of an unique total solution for clinical mass spectrometry testing: fully automated, integrated and CE system IVD-compliant Core Lab cobas c703 Introducing high-throughput clinical chemistry testing t
Slide 76: Invitation to Roche Diagnostics Investor Day 2024
Invitation to Roche Diagnostics Investor Day 2024 Innovating Diagnostics, shaping healthcare, changing lives cobas i601 mass spectrometry system Highlights: • Mass spectrometry • Continuous glucose monitoring • Next generation sequencing • Point of care • Upcoming molecular diagnostics launches • Ne
Slide 77: Doing now what patients need next
Doing now what patients need next